229 related articles for article (PubMed ID: 10862203)
21. Role of Skip Mediastinal Lymph Node Metastasis for Patients With Resectable Non-small-cell Lung Cancer: A Propensity Score Matching Analysis.
Wang L; Zhan C; Gu J; Xi J; Lin Z; Xue L; Ge D; Wang Q
Clin Lung Cancer; 2019 May; 20(3):e346-e355. PubMed ID: 30665872
[TBL] [Abstract][Full Text] [Related]
22. Operative results of non-small cell lung cancer clinically presenting mediastinal lymph adenopathy.
Yoshino I; Yamaguchi M; Yohena T; Kameyama T; Kometani T; Osoegawa A; Maehara Y
Fukuoka Igaku Zasshi; 2003 Aug; 94(8):250-8. PubMed ID: 14579727
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors after complete resection of pN2 non-small cell lung cancer.
Sonobe M; Date H; Wada H; Okubo K; Hamakawa H; Teramukai S; Matsumura A; Nakagawa T; Sumitomo S; Miyamoto Y; Okumura N; Takeo S; Kawakami K; Aoki M; Kosaka S;
J Thorac Cardiovasc Surg; 2013 Oct; 146(4):788-95. PubMed ID: 23810113
[TBL] [Abstract][Full Text] [Related]
24. Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection.
Marulli G; Verderi E; Zuin A; Schiavon M; Battistella L; Perissinotto E; Romanello P; Favaretto AG; Pasello G; Rea F
Interact Cardiovasc Thorac Surg; 2014 Aug; 19(2):256-62; discussion 262. PubMed ID: 24824495
[TBL] [Abstract][Full Text] [Related]
25. Expression of proliferating cell nuclear antigen and CD44 variant isoforms in the primary and metastatic sites of nonsmall cell lung carcinoma with intrapulmonary metastases.
Fukuse T; Hirata T; Naiki H; Hitomi S; Wada H
Cancer; 1999 Oct; 86(7):1174-81. PubMed ID: 10506701
[TBL] [Abstract][Full Text] [Related]
26. Skip mediastinal nodal metastases in the IIIa/N2 non-small cell lung cancer.
Ilic N; Petricevic A; Arar D; Kotarac S; Banovic J; Ilic NF; Tripkovic A; Grandic L
J Thorac Oncol; 2007 Nov; 2(11):1018-21. PubMed ID: 17975493
[TBL] [Abstract][Full Text] [Related]
27. [Expression and significance of E-cadherin, CD44v6, and proliferating cell nuclear antigen in non-small cell lung cancer].
Weng MX; Wu CH; Yang XP
Ai Zheng; 2008 Feb; 27(2):191-5. PubMed ID: 18279620
[TBL] [Abstract][Full Text] [Related]
28. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.
Betticher DC; Hsu Schmitz SF; Tötsch M; Hansen E; Joss C; von Briel C; Schmid RA; Pless M; Habicht J; Roth AD; Spiliopoulos A; Stahel R; Weder W; Stupp R; Egli F; Furrer M; Honegger H; Wernli M; Cerny T; Ris HB
J Clin Oncol; 2003 May; 21(9):1752-9. PubMed ID: 12721251
[TBL] [Abstract][Full Text] [Related]
29. Preoperative prognostic factors for pN2 non-small cell lung cancer.
Tomita M; Matsuzaki Y; Shimizu T; Hara M; Ayabe T; Onitsuka T
Ann Thorac Cardiovasc Surg; 2006 Feb; 12(1):15-20. PubMed ID: 16572069
[TBL] [Abstract][Full Text] [Related]
30. Analysis of risk factors for skip lymphatic metastasis and their prognostic value in operated N2 non-small-cell lung carcinoma.
Benoit L; Anusca A; Ortega-Deballon P; Cheynel N; Bernard A; Favre JP
Eur J Surg Oncol; 2006 Jun; 32(5):583-7. PubMed ID: 16621424
[TBL] [Abstract][Full Text] [Related]
31. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications.
Andre F; Grunenwald D; Pignon JP; Dujon A; Pujol JL; Brichon PY; Brouchet L; Quoix E; Westeel V; Le Chevalier T
J Clin Oncol; 2000 Aug; 18(16):2981-9. PubMed ID: 10944131
[TBL] [Abstract][Full Text] [Related]
32. Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease.
Keller SM; Vangel MG; Wagner H; Schiller JH; Herskovic A; Komaki R; Marks RS; Perry MC; Livingston RB; Johnson DH;
J Thorac Cardiovasc Surg; 2004 Jul; 128(1):130-7. PubMed ID: 15224032
[TBL] [Abstract][Full Text] [Related]
33. Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014).
Grossi F; Spizzo R; Bordo D; Cacitti V; Valent F; Rossetto C; Follador A; Di Terlizzi S; Aita M; Morelli A; Fasola G; Consiglieri C; Ceschia T; Beltrami CA; Belvedere O
J Thorac Oncol; 2010 Sep; 5(9):1354-60. PubMed ID: 20631638
[TBL] [Abstract][Full Text] [Related]
34. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors in resected pathologic (p-) stage IIIA-N2, non-small-cell lung cancer.
Tanaka F; Yanagihara K; Otake Y; Kawano Y; Miyahara R; Takenaka K; Katakura H; Ishikawa S; Ito H; Wada H
Ann Surg Oncol; 2004 Jun; 11(6):612-8. PubMed ID: 15150069
[TBL] [Abstract][Full Text] [Related]
36. Prognosis of completely resected pN2 non-small cell lung carcinomas: What is the significant node that affects survival?
Okada M; Tsubota N; Yoshimura M; Miyamoto Y; Matsuoka H
J Thorac Cardiovasc Surg; 1999 Aug; 118(2):270-5. PubMed ID: 10425000
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of high expression of proliferating cell nuclear antigen in non-small cell lung cancer.
Ye X; Ling B; Xu H; Li G; Zhao X; Xu J; Liu J; Liu L
Medicine (Baltimore); 2020 Apr; 99(16):e19755. PubMed ID: 32311975
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factors in surgically resected N2 non-small cell lung cancer: the importance of patterns of mediastinal lymph nodes metastases.
Casali C; Stefani A; Natali P; Rossi G; Morandi U
Eur J Cardiothorac Surg; 2005 Jul; 28(1):33-8. PubMed ID: 15953734
[TBL] [Abstract][Full Text] [Related]
39. The significance of one-station N2 disease in the prognosis of patients with nonsmall-cell lung cancer.
Misthos P; Sepsas E; Kokotsakis J; Skottis I; Lioulias A
Ann Thorac Surg; 2008 Nov; 86(5):1626-30. PubMed ID: 19049761
[TBL] [Abstract][Full Text] [Related]
40. HDGF and ADAM9 are novel molecular staging biomarkers, prognostic biomarkers and predictive biomarkers for adjuvant chemotherapy in surgically resected stage I non-small cell lung cancer.
Zhang J; Chen N; Qi J; Zhou B; Qiu X
J Cancer Res Clin Oncol; 2014 Aug; 140(8):1441-9. PubMed ID: 24770635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
